Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 290, Issue 3, 2006, Pages

  Erdely, Aaron ^a   Kepka Lenhart, Diane ^a   Clark, Melissa ^a,b   Zeidler Erdely, Patti ^a,b   Poljakovic, Mirjana ^a   Calhoun, William J ^a,b,c   Morris Jr , Sidney M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Adenosine 3 ,5 cyclic monophosphate; Interleukin 4; Nitric oxide; Real time reverse transcriptase polymerase chain reaction; Transforming growth factor

Indexed keywords

ARGINASE; CYCLIC AMP; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 4; ROLIPRAM; TRANSFORMING GROWTH FACTOR BETA; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ANTINEOPLASTIC AGENT; INTERLEUKIN 4; PHOSPHODIESTERASE INHIBITOR;

ADULT; ANIMAL CELL; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; MACROPHAGE; MOUSE; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; LUNG LAVAGE; METABOLISM; PROMOTER REGION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTINEOPLASTIC AGENTS; ARGINASE; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CYCLIC AMP; DRUG SYNERGISM; ENZYME INDUCTION; HUMANS; INTERLEUKIN-4; MACROPHAGES, ALVEOLAR; MICE; PHOSPHODIESTERASE INHIBITORS; PROMOTER REGIONS (GENETICS); ROLIPRAM; TRANSFORMING GROWTH FACTOR BETA;

EID: 33644936732     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00326.2005     Document Type: Article

References (38)

1. Beshay E, Croze F, and Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin Immunol 98: 272-279, 2001.
2. Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, and Baud L. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol 155: 2077-2084, 1995.
3. Burnouf C and Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8: 1255-1296, 2002.
4. Calhoun WJ, Reed HE, Moest DR, and Stevens CA. Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. Am Rev Respir Dis 145: 317-325, 1992.
5. Corraliza IM, Soler G, Eichmann K, and Modolell M. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun 206: 667-673, 1995.
6. Endo M, Oyadomari S, Terasaki Y, Takeya M, Suga M, Mori M, and Gotoh T. Induction of arginase I and II in bleomycin-induced fibrosis of mouse lung. Am J Physiol Lung Cell Mol Physiol 285: L313-L321, 2003.
7. Gray MJ, Poljakovic M, Kepka-Lenhart D, and Morris SM Jr. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene 353: 98-106, 2005.
8. Greten TF, Eigler A, Sinha B, Moeller J, and Endres S. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-α and nitric oxide. Int J Immunopharmacol 17: 605-610, 1995.
9. Hammermann R, Hey C, Schafer N, and Racke K. Phosphodiesterase inhibitors and forskolin up-regulate arginase activity in rabbit alveolar macrophages. Pulm Pharmacol Ther 13: 141-147, 2000.
10. Koschorreck S, Wenzel F, Fuhrmann M, and Racke K. Effects of phosphodiesterase inhibitors on L-arginine pathways in rat alveolar macrophages. Eur J Pharmacol 471: 229-236, 2003.
11. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365: 167-175, 2005.
12. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔC(T) method. Methods 25: 402-408, 2001.
13. Louis CA, Mody V, Henry WL Jr, Reichner JS, and Albina JE. Regulation of arginase isoforms I and II by IL-4 in cultured murine peritoneal macrophages. Am J Physiol Regul Integr Comp Physiol 276: R237-R242, 1999.
14. Maarsingh H, Tio MA, Zaagsma J, and Meurs H. Arginase attenuates inhibitory nonadrenergic noncholinergic nerve-induced nitric oxide generation and airway smooth muscle relaxation. Respir Res 6: 23, 2005.
15. Meurs H, Maarsingh H, and Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol Sci 24: 450-455, 2003.
16. Meurs H, McKay S, Maarsingh H, Hamer MA, Macic L, Molendijk N, and Zaagsma J. Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br J Pharmacol 136: 391-398, 2002.
17. Misson P, van den Brule S, Barbarin V, Lison D, and Huaux F. Markers of macrophage differentiation in experimental silicosis. J Leukoc Biol 76: 926-932, 2004.
18. Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, and Vichinsky EP. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 168: 63-69, 2003.
19. Morris CR, Poljakovic M, Lavrisha L, Machado L, Kuypers FA, and Morris SM Jr. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 170: 148-153, 2004.
20. Morris SM Jr. Regulation of arginine availability and its impact on NO synthesis. In: Nitric Oxide. Biology and Pathobiology, edited by Ignarro LJ. San Diego, CA: Academic, 2000, p. 187-197.
21. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 22: 87-105, 2002.
22. Morris SM Jr, Kepka-Lenhart D, and Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol Endocrinol Metab 275: E740-E747, 1998.
23. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, and Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 163: 3771-3777, 1999.
24. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, Luckner C, Doschko G, Soler G, Eichmann K, Muller FM, Ho AD, Goerner M, and Modolell M. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 105: 2549-2556, 2005.
25. Nebes VL and Morris SM Jr. Regulation of messenger ribonucleic acid levels for five urea cycle enzymes in cultured rat hepatocytes. Requirements for cyclic adenosine monophosphate, glucocorticoids, and ongoing protein synthesis. Mol Endocrinol 2: 444-451, 1988.
26. Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, and Murray PJ. Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol 172: 7565-7573, 2004.
27. Poljakovic M, Porter DW, Kepka-Lenhart D, Millecchia L, Mercer RR, Castranova V, and Morris SM Jr. Silica exposure induces arginase I expression in rat lung (Abstract). Proc Am Thoracic Soc 2: A818, 2005.
28. Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, Vanham G, Noel W, Bogaert P, Boonefaes T, Kindt A, Van den Bergh R, Leenen PJ, De Baetselier P, and Ghassabeh GH. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol 77: 321-327, 2005.
29. Raes G, Van den Bergh R, De Baetselier P, Ghassabeh GH, Scotton C, Locati M, Mantovani A, and Sozzani S. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol 174: 6561, 2005.
30. Ricciardolo FL, Zaagsma J, and Meurs H. The therapeutic potential of drugs targeting the arginase pathway in asthma. Expert Opin Investig Drugs 14: 1221-1231, 2005.
31. Soto FJ and Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 11: 129-134, 2005.
32. Spina D. The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy 3: 231-236, 2004.
33. Waddington SN, Mosley K, Cook HT, Tam FW, and Cattell V. Arginase AI is upregulated in acute immune complex-induced inflammation. Biochem Biophys Res Commun 247: 84-87, 1998.
34. Wei LH, Jacobs AT, Morris SM Jr, and Ignarro LJ. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 279: C248-C256, 2000.
35. Wu G and Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 336: 1-17, 1998.
36. Xia Y, Dawson VL, Dawson TM, Snyder SH, and Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 93: 6770-6774, 1996.
37. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, Humphrey JD, and Kuo L. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44: 935-943, 2004.
38. Zimmermann N, King NE, Laporte J, Yang M, Mishra A, Pope SM, Muntel EE, Witte DP, Pegg AA, Foster PS, Hamid Q, and Rothenberg ME. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 111: 1863-1874, 2003.